Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

Volume: 11, Issue: 1, Pages: 619 - 619
Published: Jan 30, 2020
Abstract
The clinical diagnosis of vascular dementia (VaD) is based on imaging criteria, and specific biochemical markers are not available. Here, we investigated the potential of cerebrospinal fluid (CSF) lipocalin 2 (LCN2), a secreted glycoprotein that has been suggested as mediating neuronal damage in vascular brain injuries. The study included four independent cohorts with a total n = 472 samples. LCN2 was significantly elevated in VaD compared to...
Paper Details
Title
Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
Published Date
Jan 30, 2020
Volume
11
Issue
1
Pages
619 - 619
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.